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ABSTRACT
M3 antagonist activity was assessed in
electrically stimulated human bronchial strips;
potency, onset and offset of action of
aclidinium, tiotropium and ipratropium were
determined. M2 antagonist activity was assessed
in electrically stimulated isolated human left
atria; duration of action was calculated.
Aclidinium demonstrated competitive
antagonism at M3 receptors with similar
potency to comparators. Onset of action of
aclidinium was similar to ipratropium and faster
than tiotropium (P\0.05); duration of action
was similar to tiotropium and longer than
ipratropium (P\0.05). At M2 receptors,
duration of action of aclidinium was shorter
than tiotropium and longer than ipratropium.
All antagonists exhibited a shorter duration of
action at M2 versus M3 receptors. Aclidinium
exhibited kinetic selectivity for human
bronchial versus atrial receptors, supporting a
favorable cardiovascular safety profile.
Keywords: Aclidinium; Atria; Bronchi; Human;
In vitro; Muscarinic receptors
INTRODUCTION
Muscarinic antagonists, such as aclidinium,
tiotropium and ipratropium, are known to
exert their bronchodilator effects by blocking
the actions of acetylcholine at M3 receptors on
airway smooth muscle [1, 2]. However,
interactions with muscarinic receptors outside
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of the respiratory tract confer a potential for
unwanted systemic side effects. For example,
blockade of the cardiac M2 receptors, the
principal muscarinic receptor subtype
expressed by cardiac myocytes [3–6], induces
tachycardia, considered the most severe side
effect associated with muscarinic antagonist use
[7].
Here, we report the functional potency and
duration of action of aclidinium bromide at M2
and M3 muscarinic receptors in isolated cardiac
and airway tissues of human origin compared
with tiotropium and ipratropium.
METHODS
Human lung tissue was harvested from patients
undergoing surgery for lung carcinoma and left
atrial tissue from patients undergoing cardiac
bypass surgery. None of the patients had a
history of asthma. The protocol for the use of
lung or cardiac tissues was approved by the
Ethics Committee of University Clinic Hospital
(Valencia, Spain), and informed consent was
obtained from all patients.
Fresh bronchial strips were mounted in a
superfusion chamber containing oxygenated
Kreb’s solution (KHS) at 37 C [8, 9].
Spontaneous tone was inhibited by zileuton
10 lM and fexofenadine 10 lM [10]. Electrical
stimulation at 8 Hz, over 0.5 ms and 40–50 V
was delivered as 10 s trains of square-wave pulses
every 2 min. Once responses to electrical
stimulation had stabilized, increasing and
cumulative concentrations of aclidinium,
ipratropium or tiotropium (0.03–10 nM) were
added to the stimulated bronchial strips to
measure potency at the M3 receptors.
To assess onset and offset of action,
aclidinium, ipratropium or tiotropium (all
10 nM) were added to the bronchial strips to
inhibit approximately 75% of the stable
baseline contractions induced by electrical
stimulation. After 30 min, the preparation was
washed free of antagonist and recovery of tone
was recorded for 14–15 h.
Macroscopically normal human left atrial
tissue (3–4 mm long) was mounted in a
superfusion chamber containing oxygenated
KHS at 37 C (pH 7.4). Each preparation (initial
load, 2.0 g) was connected to a force
displacement transducer, and changes in
tension were recorded. Atrial contraction was
induced by electrical stimulation at 1 Hz, over
5 ms and 2–5 V (20% higher than the threshold
for contraction). Once responses to electrical
stimulation had stabilized (60 min), carbachol
10 lM was added to the stimulated atria to
inhibit electrically induced contractions.
To measure the duration of action at the M2
receptors, aclidinium, ipratropium or
tiotropium were added to the carbachol
(10 lM)-treated atria at a concentration that
inhibited 70% of the maximum
carbachol-induced relaxation (70, 80 and
50 nM, respectively). Once inhibition of tone
was stable, the antagonists were washed out and
the atria incubated with carbachol 10 lM for
240 min.
The rates of onset (t1/2) and duration of
action (offset) of the antagonists were defined as
the time taken from antagonist addition to 50%
inhibition of tone, and from antagonist
washout to recover 50% (t1/2) [8] or maximal
recovery (tmax) of the maximum
carbachol-induced relaxation, respectively. The
concentration of antagonist required for 50%
inhibition of the electrically stimulated
contraction (IC50) and the offset (t1/2) was
calculated using nonlinear regression analysis.
Statistical significance, set at the 0.05 level,
was determined by parametric analysis of
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variance, using two-sided statistical tests,
followed by Bonferroni’s multiple comparison
test. All data analyses were performed using
GraphPad Prism (San Diego, CA, USA).
RESULTS
Aclidinium, ipratropium and tiotropium
produced concentration-dependent relaxation
in isolated human bronchial rings. All three
muscarinic antagonists inhibited the contractile
response induced by electrical stimulation with
similar potency, as expressed by IC50 values
(Table 1).
The duration of action (offset time; at a
concentration that inhibited 75% of the
electrically stimulated contraction) of
aclidinium at the M3 receptor was significantly
longer than that of ipratropium (Table 1;
P\0.05), whereas no recovery of tone was
observed after washout of tiotropium for the
duration of the study. The onset of action of
aclidinium was similar to that of ipratropium
and significantly faster than tiotropium
(Table 1; P\0.05).
The duration of action of aclidinium at the
M2 receptor was significantly longer than that
of ipratropium and shorter than that of
tiotropium (Table 1; both P\0.05); aclidinium
inhibited the bradycardic effect of carbachol
with a longer duration of action compared with
ipratropium, but shorter than tiotropium
(Table 1). Aclidinium had a shorter duration of
action at the M2 receptor than at the
M3 receptor (Table 1).
DISCUSSION
Our results demonstrate that in human
bronchial tissue, aclidinium had a similar





















































































































































































































































































































































































































































































































































































































































































Pulm Ther (2015) 1:103–107 105
and ipratropium, although its onset of action
was significantly faster than tiotropium and its
duration of action was significantly longer than
ipratropium. These results are consistent with
previous preclinical studies in isolated guinea
pig trachea [11, 12]. The faster onset of action of
aclidinium compared with tiotropium and the
long duration of action of both are consistent
with the clinical profile of these compounds
[13].
In human left atrial tissue, aclidinium had a
shorter duration of action at M2 receptors than
tiotropium, but longer than ipratropium. These
results are also consistent with those previously
described in isolated guinea pig left atria and in
membranes expressing human M2 receptors
[11, 12]. All three antagonists have a faster
offset from human left atrial tissue compared
with human bronchial tissue, indicating that in
human tissue isolates, each compound is
kinetically selective. Similar findings have
been demonstrated in guinea pig tissue [12],
indicating functional selectivity is maintained
across species.
CONCLUSION
These results, together with the high plasma
hydrolysis rate of aclidinium in comparison
with tiotropium [14], may translate into a
reduced propensity for systemic effects,
particularly unwanted cardiovascular adverse
events in the clinical setting, and there is
increasing evidence to support this hypothesis
[15–17].
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